newsfilter
← Latest News
GlobeNewswire·

Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline

  • Turn Therapeutics (NASDAQ: TTRX) entered a global supply, development, & license agreement with Medline on Oct. 30, 2025.
  • The partnership focuses on developing, manufacturing, & commercializing products using Turn's proprietary PermaFusion® delivery platform.
  • Medline will leverage its global distribution infrastructure to accelerate Turn's entry into professional & consumer markets.
  • All financial terms, specific product categories, & development timelines remain confidential.
  • Medline is the largest provider of medical-surgical products with over 43,000 employees operating in more than 100 countries.
  • Turn Therapeutics holds three FDA clearances for wound & dermatology formulations while advancing late-stage clinical programs for eczema & onychomycosis.
  • Turn is also pursuing global health initiatives involving thermostable vaccine delivery for underserved areas.